sitem-insel AG

Dr. Andreas Wallnoefer



Modules

Translational Medicine and Biomedical Entrepreneurship:


Biography

Andreas trained as Clinical Pharmacologist and has additional degrees in Pharmaceutical Medicine and Business Management (EMBA, IMD Lausanne).  He joined F. Hoffmann- La Roche after a Clinical Research Fellowship at the University Hospital of Leiden.  At Roche he was initially responsible for Clinical “Proof of Concept” studies and later took on the leadership for several early and late stage Clinical Development programs and successful filings. In 2007, he became Global Head of Clinical Research & Exploratory Development. Under his leadership Discovery Research and Clinical Research became better connected and translational medicine became a key driver to implement the Personalized Healthcare strategy of Roche.

After Roche’s acquisition of Genentech he was appointed 2010 as Senior Vice President and Head of Roche pRED Development. In 2012 he took on, - in addition -, the role of Head of the Cardiovascular & Metabolism Disease (CVM) R&D business unit. In 2014 Roche decided to exit the CVM franchise for strategic reasons and Andreas decided to leave Roche.

He subsequently founded a Life Sciences Consulting company and advised management and boards of biotech companies on R&D strategy, drug development and organizational management. Between 2016 and 2017 Andreas acted as interim Head of Development of Polyphor Ltd., a Swiss biotech company and revised the strategy of their lead clinical antibiotic program. He led Polyphor with a small team successfully through the regulatory meetings with FDA and EMA, which subsequently allowed an IPO of the company at SIX, Swiss Stock Exchange in 2018.  Andreas is currently the Vice Chair of the Board of Directors.

In 2016, Andreas joined in his principal role as General Partner BioMed Partners, a leading Swiss and European Venture Capital company. In the current BioMed Fund III, Andreas led the investment and is board member of four early companies Amal SA (Geneva), Tolremo Therapeutics Ltd (ETH Zurich), Alentis Ltd. (Basel & Strasbourg) and Azafaros BV. (Leiden & Basel). Amal was acquired in summer 2019 by Boehringer Ingelheim for up to 430 mio €.